# Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

> **NCT02247375** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 26 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Low dose of BIIL 284 BS tablets
- **DRUG:** High dose of BIIL 284 BS tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02247375
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2000-05
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247375, "Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02247375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*